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Systemic lupus erythematosus (SLE) is a multisystem disease characterized by B cells producing autoantibodies against nuclear
proteins and DNA, especially anti-double-strand DNA (dsDNA) antibodies. RP105 (CD180), the toll-like receptor- (TLR-)
associated molecule, is expressed on normal B cells. However, RP105-negative B cells increase in peripheral blood from patients
with active SLE. RP105 may regulate B-cell activation, and RP105-negative B cells produce autoantibodies and take part in
pathophysiology of SLE. It is possible that targeting RP105-negative B cells is one of the treatments of SLE. In this paper, we
discuss the RP105 biology and clinical signiﬁcance in SLE.
1.Introduction
Systemic lupus erythematosus (SLE) is a prototypical mul-
tisystem disease characterized by dysfunction of T cells
and polyclonal B-cell activation [1–4]. Although the patho-
genesis of the autoimmune mechanisms in SLE is not
fully understood, B cells producing autoantibodies against
nuclear proteins and DNA, especially anti-double-strand
DNA (dsDNA) antibodies, may be responsible for tissue
d a m a g e sa se ﬀector cells [5].
To date, the eﬀective methods of target therapy for
autoantibody-producing B cells for itself have not been
established yet. RP105 (CD180), the toll-like receptor-
(TLR-) associated molecule, is expressed on normal B cells
[6]. We reported that RP105-negative B cells, that lacked
RP105 expression on the surface, increase in peripheral
blood from patients with active SLE [7]. It was proved that
RP105-negative B cells produce autoantibodies, including
anti-ds-DNA antibodies, in vitro [8].
These results suggest that RP105 may function as a
negative regulator of B-cell activation. Recently, it was
proved that RP105 is a negative regulator for TLR-4 in
immune reactions in dendritic cells (DCs) [9, 10]. RP105
also regulates TLR-8 and TLR-9 responses and functions
to limit autoreactive B-cell activation [11]. Moreover, it is
possible that in the condition of high levels of BAFF (B cell-
activating factor belonging to the TNF family) and APRIL
(a proliferation-inducing ligand), RP105-negative B cells
maintain autoreactivity in autoimmune diseases through
BCMA (B-cell maturation antigen). Therefore, RP105-
negative B cells are one of the target cells for treatment of
SLE. In this paper, we discuss the RP105 biology and clinical
signiﬁcance in SLE.
2.RP105(CD180) Biology
A type I transmembrane receptor, RP105 (radio protective
MW105), was originally discovered as a surface marker of B
cells in mice and humans [6, 12]. However, the molecules
also express on monocytes [7], macrophages, and dendritic
cells. RP105 has leucine-rich repeat (LRR) motifs, similar to
the other TLRs with extracellular LRRs. The LRR is a motif
involved in protein-protein interaction [13]. The molecules
having LRRs take part in the recognition of exogenous
pathogens and subsequent activation of the immune system
in diverse species [14, 15]. The TLR was ﬁrst identiﬁed
in Drosophila [16] and has a function of triggering innate
defenses against bacterial and fungal pathogens. In humans,
LRR molecules are also important in the defense against
pathogens.
The fact of structural similarity of the extracellular
domain of RP105 to TLRs suggests that RP105 senses
pathogen invasion [17]. RP105 ligation by anti-RP1052 Clinical and Developmental Immunology
antibodies transmits an activation signal leading to B-cell
proliferation, resistance against radio-induced apoptosis,
and costimulatory molecule expression of CD86, in mice
[6]. However, RP105 lacks a conserved intracellular signaling
domain (Toll-IL-1 receptor domain; TIR domain) and has
a very short cytoplasmic tail, 11-amino-acids [18]. RP105
forms a complex with soluble protein MD-1, making het-
erodimer complex on surface of B cells [6, 17, 19]. MD-1
is essential for expression of RP105 on cell surface, similar
to MD-2 for TLR-4. Although signaling molecules binding
to tail of RP105 have not been identiﬁed yet, RP105 liga-
tion triggers Lyn, Bruton tyrosine kinase (BTK), mitogen-
activated protein kinase (MAPK),and NF-kB activation. The
results of RP105- and MD-1-deﬁcient mice showed that
activation of B cells, including antibody production, CD86
expression, and proliferative response to LPS, was reduced
[19].
On the other hand, it have been recently reported that
RP105 has a negative regulatory function for TLR-4/MD-
2 signal [9, 10]. We also investigated the role of RP105 in
thedevelopmentofcollagen-inducedarthritis(CIA).RP105-
deﬁcient mice accelerated the onset of arthritis and increased
severity. The results indicate that RP105 regulates the
antigen-presenting cell function and Treg development [10].
Interestingly, B cells activated with anti-RP105 antibodies
show growth arrest and apoptosis upon antigen receptor
signaling [20].
Collectively, in mice, RP105 may be considered to
regulate the growth and death of B cells. However, in human,
it has not been clariﬁed yet which function is predominant.
The information of RP105 obtained mainly from mice; there
had been little information in human. Therefore, we started
the study of RP105 in human SLE, in which autoantibody-
producing and activated B cells play pivotal roles.
3.RP105 inSLE
SLE is a typical multisystem disease of unknown etiology
[21] characterized by dysfunction of T cells and B cells.
Together with the production of autoantibodies against
nuclear proteins and DNA, polyclonal B-cell activation is
one of outstanding features of SLE [21]. Therefore, we had
estimated that B cells producing autoantibodies, which avoid
apoptosis and maintain their activated state in peripheral
blood, may have abnormal expression of RP105.
In contrast to murine RP105, little was known about the
molecule in humans. The human homologue of RP105 has
been identiﬁed and its mAb also established in 1998 [12, 22].
Therefore, it is important to clarify the role of RP105 on B
cells in human SLE. Staining of PBMCs from SLE patients
and normal subjects was performed with anti-human CD19
and RP105 antibodies, and analyzed using FACScan. It has
been shown that RP105 is expressed on virtually all mature B
cells from normal subjects. Interestingly, however, we found
that the number of RP105-negative B cells was dramatically
increased in SLE patients [7].
It has been also suggested that the disease activity
of SLE, SLE-DAI scores, was related to the number of
RP105-negative B cells. Serial changes of RP105-negative B
cells from active SLE patients were analyzed individually
after treatment. The percentages of RP105-negative B cells
decreased as the disease turned inactive. To know B cell
function, serum levels of IgG were measured. The levels were
correlated with the percentage of RP105-negative B cells.
These results suggest that the emergence of RP105-negative
B cells in the peripheral blood closely relates to the disease
activity and B-cell function of SLE.
RP105-negative B cells disappeared in the peripheral
blood from inactive patients treated with corticosteroids [2].
It is estimated that RP105-negative B cells seem to be more
sensitive to corticosteroids than RP105-positive B cells [2].
The eﬀects of dexamethasone on the apoptosis of RP105-
negative B cells in vitro were examined. RP105-negative B
cellsunderwentspontaneousapoptosis,comparedtoRP105-
positiveBcells.DexamethasoneinducedapoptosisofRP105-
negative B cells, although in contrast, apoptosis of RP105-
positive B cells were not induced. This result may illustrate
in vivo phenomena, clearance of RP105-negative B cells, in
patients after treatment with corticoids [2].
In patients with SLE, ANA in serum is generally positive.
Therefore, ANA-negative SLE is very rare [23]. However,
ANA-negative SLE seems to be a subpopulation of SLE,
and the diagnosis may be diﬃcult in patient without
immunological disorders [24–31]. We present that RP105-
negative B cells were increased in the peripheral blood of
two patients with ANA-negative SLE [32]. The numbers of
RP105-negative B cells were associated with disease activity
even in ANA-negative SLE patients [32]. Without signiﬁcant
serological markers for SLE, examination of RP105 on B
cells may be useful in evaluation of activity. Later, the
patients turned out to be serologically positive, including
ANA, dsDNA, and anti-Sm antibody.
4.PathophysiologyofRP105-NegativeBCellsin
Autoimmune Diseases
The most important issue was to clarify the functional roles
of RP105-negative B cells in SLE. RP105-negative B cells
and -positive B cells from patients with SLE were separated
using a cell-sorter and analyzed production of IgG and IgM
antibodies in vitro. Spontaneous IgG and IgM antibodies
from RP105-negative B cells in vitro were enhanced by a
mitogen, staphylococcus aureus Cowan I (SAC), or IL-6.
Surprisingly, RP105-negative B cells but not RP105-positive
B cells produced IgM and IgG class anti-dsDNA antibodies
in the culture with activated T cells by anti-CD3 antibodies
and IL-10 [8]. These results suggest at least partially that the
populationofRP105-negativeBcellsmayincludepathogenic
autoreactive B cells subset(s).
It has been shown that B cells from RP105-deﬁcient
mice were hyporesponsive to TLR-4 and TLR-2 stimulation
[33,34],Divanovicetal.showedthatRP105directlyinteracts
with TLR-4 and negatively regulates TLR-4 signaling by
experiments using transfectant cells and RP105-deﬁcient
mice-derived DCs [9] .T h e s er e s u l t sa r es u g g e s t i v et oc o n -
sider the function of RP105 in human SLE. It is possibleClinical and Developmental Immunology 3
that loss of RP105 induced the dysregulation of TLRs and
maintain autoreactive response of B-cell hyperactivation and
production of auto-antibodies and result in autoimmunity,
ultimately.
5. Characterizationand Phenotypes of
RP105-NegativeBCells
To characterize RP105-negative B cells in SLE patients, a
multicolor analysis was performed using a ﬂow cytometry
[7]. RP105-negative B cells expressed higher levels of CD95
and CD86 but not CD80. RP105-positive B cells showed
no expression of these molecules. Although RP105-positive
B cells expressed low levels of CD38, RP105-negative B
cells expressed higher levels of CD38. Surface IgD and
IgM levels were low on RP105-negative B cells; however,
RP105-negative B cells lacked intracellular IgM but about
a half of the RP105-negative B cells had intracellular IgG.
RP105-negative B cells can produce class-switched Ig (IgG)
although it is still stored in the cytoplasm of B cells.
RP105-negative B cells were distinct from CD5-positive cells,
since almost all RP105-negative B cells were negative for
CD5. Moreover, RP105-negative B cells are CD20-negative
and CD28-positive. Therefore, RP105-negative B cells may
belong to late B cells. Also CD138 expression was dull
(submitted). The phenotype of RP105-negative B cells was
summarized as CD95-positive, CD86-positive, CD38-bright,
IgD-negative, IgM-dull, intracellular Ig-positive, large sized
B cells, which is consistent with the phenotype of activated
and eﬀector B cells diﬀerentiated into plasma cells. However,
so far, this phenotype of B cells had not been reported.
RP105-negative B cells may consist of subsets between early
plasmablasts and plasma cells. However, another possibility
that RP105-negative B cells emerge only in autoimmunolog-
ical pathogenic state could be proposed.
6.RP105-NegativeBCellsin
VariousRheumatic Diseases
The expression of RP105 on peripheral blood B cells
from patients with various types of rheumatic diseases
was examined by a ﬂow cytometer [35]. The percentages
of RP105-negative B cells varied among the diseases. The
numbers of RP105-negative B cells in the peripheral blood of
patients with Sjogren’s syndrome (SS) and dermatomyositis
(DM) were increased. In other rheumatic diseases, including
rheumatoid arthritis (RA), systemic sclerosis (SSc), angiitis
syndrome, Behc ¸et’s disease, mixed connective tissue disease
(MCTD), and polymyositis (PM), the numbers of RP105-
negative B cells were slightly increased compared with
normal subjects but the levels were low.
Although, clinically, DM and PM (except for the pres-
ence of skin manifestations) are similar, two diseases are
etiologically diﬀerent [36–38]. The involvement of humoral
immune mechanisms in DM and cellular immunity in PM
are proposed. The levels of RP105-negative B cells in the
peripheral blood of active patients with DM and PM were
analyzed by ﬂow cytometry [39]. The percentage of RP105-
negativeBcellsinPMwaslow,andincreasedRP105-negative
B cells were found in DM. Interestingly, bronchoalveolar
lavage ﬂuid from a DM patient contained a large number
of RP105-negative B cells. The increase of RP105-negative B
cells is a marker of DM, and B cell activation in DM but in
PM seems to be pathophysiologically diﬀerent.
Because it was well established that B cells from SS
patients are in a polyclonally activated state [40], it is
conceivable that a large proportion of the RP105-negative
B cells existed in SS patients [41]. RP105-negative B cells
from SS patients produced IgG and IgM spontaneously in
vitro. The production of Ig was enhanced by SAC or IL-
6. Salivary glands from some SS patients were found to
have lymphoid follicles whose germinal centers consisted
of RP105-negative B cells. A larger proportion of B cells
inﬁltrating the area other than lymphoid follicles was also
negativeforRP105.RP105-negativeBcellsmaybeassociated
with the inﬂammation and tissue damage of the salivary
glands.
We have demonstrated that the RP105-negative B cells
were signiﬁcantly increased in SLE, SS, and DM in which B
cell activation is postulated to be involved. Also, the RP105-
negative B cells were located in the impaired organs, such
as lung or salivary gland and related to autoimmunological
inﬂammation. These results suggest that RP105-negative B
cells may be one of the targets of treatment with refractory
autoimmune diseases with organ involvements.
7.FutureBiologic Agents in
the Treatment of SLE,Targeting
RP105-NegativeBCells
For treatment of SLE, one of the targeting B cell therapies
is rituximab (anti-CD20 antibodies) [42], which has shown
eﬀective response in SLE and RA patients. If possible,
the most promising therapy of SLE may be a strategy of
targeting autoantibody-producing B cells. Because RP105-
negative B cells produce anti-dsDNA antibodies, the ther-
apy of targeting RP105-negative B cells may be one of
the possible therapies for SLE. For this purpose, we are
studyingtheidentiﬁcationoftheantigensspeciﬁcforRP105-
negative B cells using DNA microarrays [43]. Diﬀerential
geneexpressionbetweenRP105-negativeandRP105-positive
B cells was analyzed and surface expression of antigens
speciﬁc for RP105-negative B cells was conﬁrmed by a
ﬂow cytometry. Although several antigens were identiﬁed,
BCMA was one of the most interesting antigens. RP105-
negative B cells from SLE patients showed more preferential
expression of BCMA compared with BAFF-R than normal
subjects and were possibly regulated by BAFF/APRIL. These
results also suggest that BCMA may be one of the target
for elimination of RP105-negative B cells to treat SLE. The
dataofBCMAexpressionsuggestthatRP105-negativeBcells
from active SLE patients may have predisposition toward
survival response in high levels of BAFF and/or APRIL in
vivo via BCMA.
Because the nonspeciﬁc immunosuppressive therapies
induce signiﬁcant adverse eﬀects and disability in autoim-
mune diseases, novel safer and more eﬀective therapies4 Clinical and Developmental Immunology
speciﬁc for pathogenic cells or molecules are required. Our
results suggest that blocking agents to the signals between
BAFF/APRIL and their receptors, especially the passage via
BCMAmaybeeﬀective.Prevention ofemerging ordepletion
ofRP105-negativeBcellsmaybeanadditionaloptionforthe
treatment of SLE patients. Further studies will be required
to determine whether targeting RP105-negative B cells could
inhibit autoantibody production and regulate autoimmune
events. Our results in human SLE would provide a new
insight of potential mechanism and intervention of B cells
in autoimmune diseases.
8. Conclusions
RP105 may regulate B-cell activation, and RP105-negative
B cells produce autoantibodies and take part in pathophys-
iology of SLE. Autoantibody-producing RP105-negative B
cells are considered as one of the therapeutic targets in SLE.
Moreover, the targeting RP105-negaive B cells would be a
speciﬁc treatment for pathogenic cells, and the eﬃcacy and
safety should be conﬁrmed in further studies.
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